NL-OMON52961招募中2 期
iPAVE - imaging Pituitary ActiVation by Exendin - iPAVE
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Inclusion criteria (patients with treatment response)
- •- Age >=18 years
- •- Subject is diagnosed with type 2 diabetes
- •- Subject showed response to GLP-1RA treatment (decrease in HbA1c >=5 mmol/mol
- •and/or weight loss >=5%)
- •- Ability to sign informed consent, Inclusion criteria (patients without
- •treatment response)
- •- Age >=18 years
- •- Subject is diagnosed with type 2 diabetes
- •- Subject showed no response to GLP-1RA treatment as classified by the treating
- •diabetologist
- •- Ability to sign informed consent
排除标准
- •- Liver disease defined as aspartate aminotransferase or alanine
- •aminotransferase level of more than three times the upper limit of the normal
- •- Renal disease defined as MDRD <40 ml/min/1.73 m^2
- •- Pregnancy or the wish to become pregnant within 6 months after the study
- •- Breastfeeding
- •- Age <18 years
- •- Pituitary disorder
- •- lnability to sign informed consent
- •- Exclusion criteria for MR:
- •* Fragments, clips or devices in brain, eyes, spinal canal
- •* Implantable defibrillator or pacemaker (wires)
- •* Mandibular magnetic implants
- •* Neurostimulator, bladder stimulator, non-removable insulin pump
- •* Metal tissue-expander in chest
- •* Cochlear implant
- •* Ossicular replacement prosthesis
研究者
相似试验
进行中（未招募）
1 期
Effects of treatment with GLP-1 receptor agonists on the HPA-axis in type 2 diabetesEUCTR2018-003566-13-NLRadboud university medical center20
已完成
不适用
Imaging Pituitary ActiVation by ExendinDiabetes Mellitus, Type 2NCT03923114Radboud University Medical Center20
已完成
不适用
Detection of pituitary neuroendocrine tumor (PitNET) tissue during endoscopic transsphenoidal surgery using Bevacizumab-800CW: a single center feasibility and dose finding studyPituitary neuroendocrine tumor (PitNET)1002111210014710pituitary adenomaNL-OMON49831niversitair Medisch Centrum Groningen15
终止
1 期
A study to see whether PET scans using a chemical called Exendin can detect metastatic prostate cancer.CancerACTRN12619000791134Mark S Stein Pty Ltd4
撤回
1 期
An imaging study of 64Cu-SARTATE using positron emission tomography in paediatric patients with high-risk neuroblastoma.ACTRN12617001259336Clarity Pharmaceuticals LTD10